World Library  
Flag as Inappropriate
Email this Article

Tametraline

 

Tametraline

Tametraline
Systematic (IUPAC) name
(1R,4S)-N-methyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine
Clinical data
Legal status
  • Legal
Identifiers
CAS number  YesY
ATC code None
PubChem
ChemSpider  N
UNII  YesY
Chemical data
Formula C17H19N 
Mol. mass 237.339 g/mol
 N   

Tametraline (CP-24,441) is the parent of a series of chemical compounds investigated at Pfizer that eventually led to the development of sertraline (CP-51,974-1).[1]

Sertraline has been called "3,4-dichloro tametraline". This is correct but it is an oversimplification in the sense that sertraline is the SS isomer whereas tametraline is the 1R,4S stereoisomer.

1R-Methylamino-4S-phenyl-tetralin is a potent inhibitor of norepinephrine uptake in rat brain synaptosomes,[2] reverses reserpine induced hypothermia in mice, and blocks uptake of [3H] into rat heart.[3]

Tametraline is a norepinephrine-dopamine reuptake inhibitor.[4]

Indatraline is an indanamine homolog of tetralin-based tametraline, although in the case of indatraline the product is pm-dichlorinated.

Contents

  • Chemistry 1
    • Cis/Trans Ratio 1.1
    • CAN radical induced dimerization of styrene 1.2
  • SAR 2
    • Enantiopurified Trans- and Cis- Aminotetraline Derivatives 2.1
    • Racemic Cis- and Trans- Aminotetraline Derivatives 2.2
  • See also 3
  • External links 4
  • References 5

Chemistry

Two routes have been previously described,[5] one for aryl moieties containing electron withdrawing groups, and one for electron donating groups:

Preparation of Tametraline: U.S. Patent 4,045,488 Reinhard Sarges; Pfizer Inc.

Sarges, R. . (1975). "Synthesis of phenyl-substituted 1-aminotetralines". The Journal of Organic Chemistry 40 (9): 1216–1224.  

"As expected, Friedel-Crafts cyclization of the diarylbutyric acid derivatives # to the most reactive ring was observed with little or none of the alternative isomer being detected."

"The KMnO4 oxidation of the 1-aryl-tetralins # was observed to give 4-hydroxy-4-aryltetralones # instead of the expected tetralone # previously reported.[5] As a result of this finding, direct oxidation of Grignard reaction product # was attempted and found to be a more efficient route."

See also: U.S. Patent 4,045,488 (and refs therein: doi:10.1021/ja01193a020 doi:10.1021/ja01183a058 doi:10.1021/ja01157a130 doi:10.1021/ja01635a052)

Cis/Trans Ratio

In the case of 3,4-dichloro product, approximately 50:50 cis-/trans- ratio was achieved, according to the reference.[4]

CAN radical induced dimerization of styrene

"A facile one-pot synthesis of 1-amino-4-aryl-tetralin derivatives by the CAN-induced (see also: CAN) cyclodimerization of various styrenes in acetonitrile and acrylonitrile is described." [1] [2] doi:10.1021/ol0257934

one-pot synthesis of 1-amino-4-aryl-tetralin derivatives by the CAN-induced cyclodimerization of various styrenes in acetonitrile and acrylonitrile

SAR

Certain aromatic substitutients have a potentiating effect (e.g., p-Br), whereas others negate the compound's intrinsic activity.

Enantiopurified Trans- and Cis- Aminotetraline Derivatives

Enantiopurified 4-aryl-aminotetralins IC50 (μM)
Stereo X Y NE DA 5-HT
RS H H 0.018 0.15 0.84
SR H H 0.37 1.40 14.00
RS Cl H 0.019 0.052 0.084
SR Cl H 0.46 1.40 3.50
RS Cl Cl 0.01 0.044 0.039
SR Cl Cl 0.044 0.27 0.47
SS Cl Cl 1.20 1.30 0.06
RR Cl Cl 0.30 0.32 0.46

Interestingly, (±)-sertraline is not entirely SERT selective until it has been resolved into the SS enantiomer.

In terms of the trans- isomers there is relatively marked separation in the activity between the RS and SR enantiomers. This stands in contrast to what has been observed in the homologous indamine class where both of the trans- enantiomers possessed significant TRI activity at all three of the monoamine transporters.

Racemic Cis- and Trans- Aminotetraline Derivatives

The primary amines are claimed to completely lack any affinity for the transporters.

See also

EXP-561 (1-amino-4-phenylbicyclo[2.2.2]octane)
  • CP-24,441 (1R, 4S-N-methyl- 4-phenyl-1,2,3,4-tetrahydro-1-naphthylamine)
  • CP-39,332 (N-methyl-4-phenyl-1,2,3,4-tetrahydro-2- naphthylamine)
  • Cyproheptadine [4-(5H-dibenz-[a,d]cyclohepten-5-ylidine)-1-methylpiperidine]
  • EXP-561 (1-amino-4-phenylbicyclo[2.2.2]octane)
  • JNJ-7925476
  • Lometraline
  • Nefopam

Sepracor has tried to patent the trans dichloro analog U.S. Patent 7,105,699.

External links

  • http://www.healyprozac.com/Book/Introduction.doc
  • http://www.zoominfo.com/people/Koe_Ken_594418650.aspx

During his 40 years at Pfizer, Koe authored more than 100 articles and papers. ... Koe learned to review previous studies and to build on findings that had failed to lead to successful products. In his early work with serotonin, for example, he studied the chemical tametraline, which proved ineffective as an anti-depressant.

Tests showed the chemical functioned more as a stimulant, a use Pfizer was not interested in pursuing. Although his research had failed to yield the desired result, Koe was convinced that the development of a viable anti-depressant was within reach.

References

  1. ^ Koe, B. K.; Weissman, A.; Welch, W. M.; Browne, R. G. (1983). "Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin". The Journal of Pharmacology and Experimental Therapeutics 226 (3): 686–700.  
  2. ^ Koe, B. K. (1976). "Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain". The Journal of Pharmacology and Experimental Therapeutics 199 (3): 649–661.  
  3. ^ Sarges, R.; Koe, B. K.; Weissman, A.; Schaefer, J. P. (1974). "Blockade of heart 3H-norepinephrine up-take by 4-phenyl-1-aminotetralines: implications for the active conformation of imipramine-like drugs". The Journal of Pharmacology and Experimental Therapeutics 191 (3): 393–402.  
  4. ^ a b Welch, W. M.; Kraska, A. R.; Sarges, R.; Koe, B. K. (1984). "Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins". Journal of Medical Chemistry 27 (11): 1508–1515.  
  5. ^ a b


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.